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The development, evaluation, and implementation of new and improved diagnostics have been identified as
critical needs by human immunodeficiency virus (HIV) and tuberculosis researchers and clinicians alike. These
needs exist in international and domestic settings and in adult and pediatric populations. Experts in tuberculosis
and HIV care, researchers, healthcare providers, public health experts, and industry representatives, as well as
representatives of pertinent US federal agencies (Centers for Disease Control and Prevention, Food and Drug
Administration, National Institutes of Health, United States Agency for International Development) assembled at
a workshop proposed by the DiagnosticsWorking Group of the Federal Tuberculosis Taskforce to review the state
of tuberculosis diagnostics development in adult and pediatric populations.
A workshop proposed by the Diagnostics Working
Group of the Federal Tuberculosis Taskforce was
convened in Silver Spring, Maryland, in June 2011 to
review the state of tuberculosis diagnostics development
in adult and pediatric populations. The objectives of the
workshop were to initiate discussion and facilitate the
identification and evaluation of diagnostic tools for
tuberculosis and tuberculosis/human immunodefi-
ciency virus (HIV) coinfection. This article, which
provides a summary of the key points discussed in
the Clinical Research and Development of Tuberculosis
Diagnostics track of the workshop, is divided by tech-
nologies and platforms currently under development or
optimization, including (1) culture-based technologies,
(2) molecular-based technologies, and (3) nonmolecular,
novel technologies for diagnosis. The objective of the
Clinical Research and Development Track was to bring
together principal groups and researchers in the field of
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tuberculosis diagnostics to (1) identify and prioritize critical and
important clinical research studies for the evaluation of current
and future tuberculosis diagnostics, (2) identify and disseminate
information regarding resources available to researchers, and
(3) coordinate research efforts to ensure expediency of re-
search critical to this field and to maximize efficient use of
available resources. The main topics of discussion included:
improving diagnostic tests; moving from silos to synergy; current
barriers and challenges with existing platforms; increasing pro-
ductivity; and collaboration. In the nearly 3 days of presenta-
tions and discussions, 2 primary themes emerged: building and
maintaining momentum and moving from silos to synergy
(see the viewpoint article from Kim et al, this supplement) .
BUILDING MOMENTUM AND MOVING FROM
SILOS TO SYNERGY FOR IMPROVED
DIAGNOSTIC TESTING
After a long drought in the tuberculosis diagnostics pipeline,
the timing is right to take advantage of a powerful range of
innovative technologies, along with increased potential for
new molecular approaches, making it more critical than ever
to work together efficiently and productively. The World
Health Organization (WHO) objectives for tuberculosis test
development include the need to (1) simplify and improve
detection of tuberculosis cases, particularly point-of-care
(POC) tests with same-day results; (2) enable more effective
monitoring of tuberculosis treatment for latent and active
cases; (3) rapidly identify drug resistance to first- and second-
line antituberculosis medicines; and (4) reliably identify latent
tuberculosis infection and determine the risk of progression
to active disease. This workshop highlighted that no single
group has enough resources to take on research in tuber-
culosis diagnostics alone. Adaptation and enhancement of
existing resources and coordinated strategies and research
agendas will be needed for efficient development of novel
diagnostics (Figure 1). Prioritization of the scientific agenda
in the context of information and data sharing among the
stakeholders should occur at all levels, possibly through the
development of a Tuberculosis Diagnostics Research Forum
that would prevent redundancy and bring researchers and
clinicians closer to synergy in the collective search for im-
proved tuberculosis diagnostics. Table 1 shows selected
leading tuberculosis diagnostics, as well as those in advanced
stages of development.
CULTURE-BASED TECHNOLOGIES
Worldwide, acid-fast bacilli (AFB) sputum smear micros-
copy is the most widely used method for identifying tuber-
culosis cases. It is inexpensive and rapid. Overall, however,
AFB smear-based diagnosis has several major drawbacks,
including low sensitivity and insufficient specificity, partic-
ularly in individuals who are HIV-infected; the absence of
drug-susceptibility information; and, importantly, signifi-
cant differences in performance depending on the operator
[1–3]. As a consequence, sputum culture remains the rec-
ognized gold standard for confirming diagnosis of tubercu-
losis, despite the delays and complexities involved with
culture-based diagnostics. Culture improves the sensitivity
and specificity of mycobacteriology for the diagnosis of tu-
berculosis; it provides live bacteria by which drug suscepti-
bility and genotyping can be assessed as a method for treatment
monitoring; it is the most studied; and it is applicable
broadly to sputum, urine, pleural fluid, cerebrospinal fluid,
and biopsied or excised tissue, among other specimen types.
However, the need for biosafety facilities and specially
trained staff to perform the necessary procedures, issues of
cross-contamination, lack of standardized methodology, delays
in diagnosis, and lack of access in high-burden countries
remain flaws of conventional culture methods [4–6]. Using
this paradigm, globally around one-third of tuberculosis
cases go undetected, detection in children remains poor, as
many as 20% of tuberculosis cases in HIV infection are
culture negative, and only a small proportion of multidrug-
resistant (MDR) tuberculosis is recognized at the time of
initial tuberculosis diagnosis [4, 7].
Cultures using liquid media are more sensitive and faster
in reaching a diagnosis than most traditional techniques,
which use egg-based solid media, although culture using
thin-layer synthetic agar improves the performance of solid
culture media [8, 9]. Efforts to automate and streamline
components of culturing Mycobacterium tuberculosis have
led to development of several commercial liquid-culture-
based technologies. These include the BacT/Alert 3D System
(bioMe´rieux), the Versa TREK system (Trek Diagnostic
Systems), the BACTEC MGIT 960 system (Becton Dickinson),
and the microscopic-observation drug-susceptibility assay
(MODS; Hardy Diagnostics). Confirmation of M. tuberculosis
speciation and differentiation from other mycobacteria us-
ing these systems is commonly achieved with nonmolecular
approaches including the MGIT TBc Identification Test (TBc ID,
Becton Dickinson) and Capilia TB (TAUNS), both MTP64-based
immunochromatographic assays, and concurrent culture or sub-
culture in selective agents such as p-nitrobenzoic acid [10–12].
The MODS assay is based on the detection of the characteristic
morphology of tuberculosis under an inverted light micro-
scope, is accurate and rapid [13], and usually involves the
identification of M. tuberculosis and MDR tuberculosis
concurrently, which is infrequently included in other liquid-
culture techniques [14, 15]. The first-line antituberculosis
drugs isoniazid and rifampicin are incorporated into the
MODS assay, permitting simultaneous direct testing for
MDR tuberculosis. A low-cost, all-reagents-provided MODS
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test kit has recently been developed for commercial sale,
addressing a common limitation of all noncommercial di-
agnostic tests, that of lack of standardization.
Despite the advances in and automation of liquid-
culture-based technologies and the fact that positive culture
represents the gold standard for diagnosis, there continue to
be significant challenges with these techniques, including
cost, logistics of specimen handling and specimen transport,
biosafety precautions, and the need for extensive personnel
training [6]. These concerns notwithstanding, a recent WHO
policy statement recommends implementation of liquid-culture
systems as part of a country-specific comprehensive plan for
laboratory capacity strengthening [8]. Field and cost-effectiveness
studies are required to assess the impact of such practice on
tuberculosis control worldwide [16]. The development of an
assay, culture based or otherwise, ends with assessments of
implementation and outcomes, and innumerable challenges
must be considered and addressed on the road to successfully
rolling out new diagnostics [6]. In addition to the need for
field studies, there remain a number of procedural issues as
well as scientific questions related to smear-based diagnosis
and culture-based technologies that deserve further study
[2]. As an example, it is well recognized that liquid cultures
are generally more prone to contamination [17]. Specimen
handling, particularly as it relates to decontamination proce-
dures, needs to be further studied and better standardized to
optimize M. tuberculosis culture yield, while minimizing con-
tamination and the risk of M. tuberculosis cross-contamination,
which causes false-positive cultures. The impact of poly-
clonal infection on the accuracy of diagnostics and disease
outcomes deserves further study. In HIV-associated tuber-
culosis, polyclonal infection has been reported both as 2
strains in concurrent sputum as well as the isolation of dif-
ferent sputum and blood strains, and may represent a com-
bination of reactivation disease and newly acquired infection
[12]. Existing liquid-culture systems do not identify polyclonal
infection. Another area of interest relates to the role of re-
suscitation promoting factor (RPF) dependence within a pop-
ulation of M. tuberculosis cells on culture-based detection [18].
RPFs are a family of secreted proteins produced by M. tuber-
culosis that stimulate mycobacterial growth. RPF-dependent M.
tuberculosis cells in sputum may vary widely between patients
and during times of treatment. It has been hypothesized that
M. tuberculosis populations detected by RPF supplementa-
tion and the identification of lipid-body-rich cells by mi-
croscopy may provide a view into the persister population
and could open up new possibilities for monitoring treat-
ment response [19].
Figure 1. Conceptual framework for building momentum and moving from silos to synergy for improved diagnostic tests.
Clinical R&D of Tuberculosis Diagnostics d JID 2012:205 (Suppl 2) d S161
 
Table 1. Tuberculosis Diagnostics: Approved Modalities and Those in Advanced Stages of Development
Modality Example Strength Weakness Sensitivity Affordability Simplicity
Principal
Setting
Speed of
Detection
Smear microscopy Ziehl-Neelsen,
Auramine
Minimal equipment
required; low cost
Poor sensitivity, especially for
extrapulmonary tuberculosis,
children, and HIV coinfection;
operator-dependent; no DST
Low Inexpensive Simple Local labs Rapid
Traditional solid
culture on
egg-based media
Ogawa,
Lowenstein-Jensen
Low cost; simple;
robust; can
provide DST
Some biosafety concerns;
DST usually delayed after
detection; poorly standardized;
moderate sensitivity
Moderate Moderate Simple Regional labs Slow
Modern culture on
synthetic media
BACTEC MGIT,
thin-layer agar
Sensitive; provides
DST; well validated
for extrapulmonary
tuberculosis
Biosafety concerns; training
and equipment requirements;
cross-contamination and
inability to detect polyclonal
infection (liquid); DST usually
delayed after detection;
requires international cold
chain supplies
High Moderate/
Expensive
Moderate Regional labs Intermediate
MODS In-house protocol;
Hardy kit
Simultaneous DST;
sensitive; rapid
for culture
Biosafety concerns; training and
equipment requirements;
requires international cold
chain supplies
High Moderate/
Expensive
Moderate Regional labs Intermediate
NAAT Amplicor, Gen-Probe,
LAMP, GeneXpert
Simultaneous DST;
most tests are
simple; biosafety
Genotypic DST has uncertain
clinical implications;
moderate sensitivity
Moderate Moderate/
Expensive
Moderate/
Simple
Local/
Regional labs
Rapid
Line probe INNO-LiPARif,
MTBDR
Provides rapid DST
for patients
known to have
tuberculosis
Expensive; complex; principally
used for DST, not tuberculosis
diagnosis; genotypic DST has
uncertain clinical implications;
requires international
cold chain supplies
Low Expensive Complex Regional labs Rapid
LAM TB ELISA Nonsputum based Low sensitivity in HIV-uninfected
patients
Low Undefined Moderate Regional labs? Rapid
Abbreviations: DST, drug-susceptibility testing; HIV, human immunodeficiency virus; LAM, lipoarabinomannan; LAMP, loop-mediated isothermal amplification; MODS, microscopic-observation drug susceptibility; NAAT,
nucleic acid amplification tests.
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MOLECULAR-BASED DETECTION OFM.
TUBERCULOSIS
Diagnostic molecular technologies have improved since the
1990s, with more and better molecular biology techniques,
among them polymerase chain reaction (PCR)–based tech-
nologies, fluorescent in situ hybridization, peptide nucleic
acids, electrochemical detection of DNA, biochips, nano-
technology, and proteomic technologies [20]. Most of the
molecular-based technologies, designed with fast-growing
organisms in mind, are now applied to the diagnosis of slow-
growing pathogens such as M. tuberculosis. Nucleic acid
amplification tests (NAATs) are routine procedures in many
settings because they are specific and reliable, with detection
of M. tuberculosis in specimens several weeks earlier than
culture (results available within 24–48 hours of sample receipt)
[21]. NAATs can be developed in-house or are available
commercially, based on PCR or other technologies, and are
fully or partially automated. Sensitivity, however, in some
commercial and in-house assays has been variable [22, 23],
especially in testing of smear-negative samples. The recently
published Centers for Disease Control and Prevention
(CDC) guidelines suggest that NAATs will become standard
practice in the United States for patients with suspected
tuberculosis and that all clinicians and public health programs
should have NAATs available to lessen time to diagnosis [24].
Commercial direct amplification tests include Amplicor (Roche
Diagnostic Systems), based on PCR of 16S ribosomal RNA
(rRNA), and the Amplified MTD (M. tuberculosis Direct) test
(Gen-Probe) based on transcription-mediated amplification
of rRNA. Both are approved by the US Food and Drug
Administration (FDA) for direct tuberculosis detection in
sputum samples, but only Gen-Probe is commercially available in
the United States. Loop-mediated isothermal amplification
(LAMP) is another new NAAT that can be used in areas with
limited resources because expensive and complex instruments
are not needed [25]. LAMP-based assays have targeted gyrB
[25, 26], rrs [27], and more recently, the repetitive insertion
sequence IS6110 for the detection of M. tuberculosis in clinical
sputum samples. The IS6110-based LAMP assay may be a test
with higher sensitivity than assays that are based on gyrB and
rrs and, if confirmed, would be a good candidate for use in
developing countries [28].
The recently developed Xpert MTB/RIF test (hereafter
referred to as Xpert) on the GeneXpert platform (produced
by Cepheid with support and funding from US federal
agencies; the National Institutes of Health [NIH], National
Institute of Allergy and Infectious Diseases [NIAID]; and the
Foundation for Innovative and New Diagnostics [FIND],
funded by the Bill & Melinda Gates Foundation) is an au-
tomated molecular-beacons-based approach to diagnosing
M. tuberculosis and rifampin resistance [29, 30]. Molecular
beacons are hybridization probes that, when attached to
their target, emit fluorescence. The Xpert test has been
shown to have high sensitivity and specificity for detection of
M. tuberculosis and associated rifampin resistance in high-
incidence settings, and plans are in place to pursue FDA
approval for use of the test in the United States. Capable of
providing results in less than 2 hours, Xpert may also reliably
diagnose extrapulmonary tuberculosis [31]. Due to the au-
tomated, rapid, and sensitive nature of the test, Xpert has
been endorsed by WHO and is to be rolled out as part of
national plans for tuberculosis and MDR tuberculosis care
and control [32]. A recent implementation of Xpert in South
Africa highlighted the need for clinical pathways and algo-
rithms for the optimal integration of the test into tubercu-
losis programs. For example, management of HIV-infected
persons with suspected tuberculosis who test negative, among
other clinical scenarios, warrants the study and institution of
such algorithms.
The development of molecular diagnostics into automated
systems, such as the Xpert assay, has identified new areas of
research. These include assessing how to optimize sensitivity
in nonrespiratory specimens for use in extrapulmonary and
pediatric tuberculosis; determining whether semiquantitative
test outputs can be used for treatment monitoring; determining
the optimal settings in which these tests might replace AFB
smears, culture, or both; evaluating the use of Xpert as an
infection control tool; determining the frequency of false
positives for rifampin resistance; and measuring the pre-
dictive value of Xpert as a diagnostic in low-incidence set-
tings [33]. In addition, the cost and cost–benefit of Xpert and
other potential NAATs need to be studied, with recognition
of the fact that actual test costs extend beyond the cost of the
cartridges and reagents and include costs for transport, person-
nel training, maintenance, waste disposal, mechanisms for
assuring quality, and secure locations for storage. Similarly,
when comparing these expenses to the use of the broadly
available and inexpensive AFB smear, the costs of repeat
testing as well as the societal costs of delayed and missed
diagnoses given the low sensitivity of this method for diagnosis
also need to be considered.
MOLECULAR-BASED DETECTION OF DRUG
RESISTANCE
Two rapid molecular tests have recently been implemented
to screen patients at high risk for drug-resistant tuberculosis.
Also known as line probe assays, the rapid tests are the
INNO-LiPARif.TB assay (Innogenetics) and the GenoType
MTBDR assay (Hain Lifescience). They are available globally
but are not yet FDA approved for use in the United States.
INNO-LiPARif.TB can detect the presence of M. tuberculosis in
addition to mutations associated with rifampin resistance [16].
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The assay does not detect mutations associated with isoniazid
resistance, but it is believed that the majority of isolates with
mutations conferring rifampin resistance also have mutations
that confer isoniazid resistance. A recent study, however, has
shown that the presence of rifampin resistance alone may not be
a reliable marker to diagnose MDR tuberculosis [34].
The GenoType MTBDR is a DNA strip assay developed
for the rapid detection of gene mutations associated with
rifampin and isoniazid resistance (rpoB and katG) in clinical
isolates [35]. Evaluations of GenoType MTBDR assays con-
ducted by several research groups have been published, and
generally the reviews have attested to the excellent accuracy
for rifampin resistance [36]. Several groups have shown that
the specificity of this assay for isoniazid is also excellent, but
sensitivity is variable [37–39]. The GenoType MTBDRplus,
developed to detect a broader variety of rpoB and inhA gene
mutations, appears to have enhanced the assay’s detection of
isoniazid resistance [35].
Clinicians are currently using molecular information
concerning drug resistance to influence and guide thera-
peutic decisions. Genotypic methods have the potential to
meet the increasing need for fast and accurate assessment of
drug-susceptibility testing, but increased research in this
area is clearly needed. The CDC offers a molecular detection
of drug resistance service to provide rapid results on a wide
range of specific mutations and evidence of mixed populations
ofM. tuberculosis (http://www.cdc.gov/tb/topic/Laboratory/mddr.
htm). The platform involves semiautomated conventional PCR
and DNA sequencing that can be readily expanded to acco-
mmodate additional loci in the sequencing panel as quickly
as new mutations associated with resistance are identified.
There are several gaps and challenges in the molecular
detection of drug resistance. For instance, not all mutations
that account for specific types of drug resistance are known
(eg, pyrazinamide, the fluoroquinolones, and ethambutol)
[40]. Given the recent renaissance in terms of new drugs under
development for drug-resistant tuberculosis, development of
tools for the rapid detection of both MDR and extensively
drug-resistant tuberculosis is a critical need. Researchers
have also recovered heterogeneous populations of bacilli
with different resistance mutations from a single patient’s
sputum [41]. The implication of genetic heterogeneity may
be the simultaneous presence of drug-resistant and drug-
susceptible phenotypes, both of which may require targeted
treatment. Indeed, there are still challenges in deciphering
what the clinical implications of identifying mutations are,
how mutations cause drug resistance, and how to incorporate
knowledge of mutations into molecular detection methodolo-
gies. Drug resistance is probably more complicated than initial
paradigms have predictedda single mutation can confer re-
sistance to multiple drugs or multiple gene mutations could
result in resistance to a single antimicrobial [42].
An available resource for tuberculosis researchers is data
from whole genome sequencing in almost 50 drug-resistant
strains compared with whole genome sequencing of drug-
susceptible strains (publicly available at http://www.tbdreamdb.
com/). The database is interactive, allowing it to serve as
a resource for the development of molecular diagnostics and
surveillance tools for tuberculosis. In addition, the database
is useful for the structural mapping of mutations to better
understand the mechanisms of drug resistance for novel
pharmaceutical design. One of the utilities of this database
has been a better understanding of the fact that isoniazid-
resistant strains often have multiple gene mutations. The
results of DNA sequencing of 28 genes associated with drug
resistance in 1600 M. tuberculosis strains will also be made
public in the near future in usable form. The TubercuList
(http://tuberculist.epfl.ch/) is another server constructed
around a database of DNA and protein sequences derived
from a paradigm M. tuberculosis strain [43]. Information
about the genomes of the tubercle bacilli can be retrieved and
analyzed using various criteria, for example, keywords, gene
names, or locations.
In general, this workshop session concluded that a fuller
sequencing of resistant strains was needed, that public data-
bases on mutations causing resistance should be curated on
an ongoing basis, and that confirmation of resistance-causing
mutations through the creation and phenotyping of point
mutants was an important research goal. Drugs identified as
high priority for future research and incorporation into rapid
diagnostics include pyrazinamide, the fluoroquinolones, and
ethambutol. In summary, novel tools are urgently needed for
rapid diagnosis of drug-resistant tuberculosis. Knowledge about
mutations that lead to antimicrobial resistance as well as an
understanding of the relative occurrence of specific mutations
can spur the development of better diagnostic tools.
NONMOLECULAR DIAGNOSTIC
TECHNOLOGIES
Several nonmolecular approaches to discovery of tubercu-
losis diagnostic biomarkers are emerging, among them optic
methods, automated optics, and nonoptics, including mag-
netic bead technologies, clustered magnetic nanoparticles,
electronic nose assays, lateral flow assays, and -omics. Bio-
markers are molecular featuresdmolecules, genes, or char-
acteristicsdthat can identify and/or monitor a particular
physiological process or disease in the host [44]. For exam-
ple, researchers have screened urine samples, serum, and
saliva searching for evaluable markers through any variety
of platformsdgenomic, proteomic, metabolomic, lipidomic,
and glycomic. New technologies are being developed and tested
for identification of biomarkers for active tuberculosis, with
a particular focus on pathogen-specific markers. For host-based
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markers, surface-enhanced laser desorption/ionization time-
of-flight mass spectrometry, a type of proteomic fingerprint
technology, has been used to screen for potential protein
biomarkers in serum for the diagnosis of tuberculosis [45].
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry has also been used to profile the serum
proteome and has identified several host biomarkers that
differentiate individuals with tuberculosis from controls
with some accuracy [46]. FIND and its partners have used
a high-throughput cloning and expression method to examine
the entire tuberculosis proteome in order to carry out se-
rological profiling against antigen arrays and identify anti-
body biomarkers that might be targets for POC diagnostic
tools [47].
Given the limitations of sputum as a diagnostic specimen,
for example, in children or in extrapulmonary disease, the
availability of a nonsputum-based, nonculture-based di-
agnostic in high-burden settings would represent a signifi-
cant advancement in tuberculosis control (see McNerney
et al, this supplement). Lipoarabinomannan (LAM), a 17.5-kD
heat-stable glycolipid within the cell wall of M. tuberculosis, is
one potential nonculture-based, nonmolecular-based marker
of active tuberculosis [48]. To diagnose tuberculosis in HIV-
infected patients with advanced immunosuppression, a LAM
lateral flow assay (Clearview TBELISA, Inverness Medical
Innovations) was developed. It has been tested using urine,
sputum, and cerebrospinal fluid and is currently being as-
sessed in clinical trials. A recent study of HIV-coinfected
patients in South Africa found that the assay was not suffi-
ciently sensitive to replace culture [49]. A similar assay, the
urine LAM-ELISA (Chemogen) was evaluated in tubercu-
losis patients with and without HIV coinfection. The con-
clusion was that the assay does not appear to be useful as an
independent diagnostic for pulmonary tuberculosis [50].
Whether the assay could serve as a supplemental device in
the diagnosis of HIV-associated tuberculosis is still under
investigation [51, 52].
An example of optical methods for the diagnosis of tuber-
culosis is the application of reporter enzyme fluorescence
(REF) to whole animal imaging. Recently published studies
have demonstrated that the enzyme ß-lactamase, expressed by
bacteria but not their eukaryotic hosts, can be used along with
near-infrared fluorogenic substrates to detect pulmonary tuber-
culosis infections in real time in mice [53]. Because the crystal
structure of M. tuberculosis ß-lactamase is known, researchers
can design specific substrates that are distinctly different from
other bacterial ß-lactamases. The primary improvement of
REF over other types of systems is that REF does not require
recombinant strains that can introduce foreign genes that
may unpredictably interfere with bacterial physiology, es-
pecially when expressed from plasmids. REF permits sensi-
tive detection of M. tuberculosis whether in vitro or in vivo.
Thus, this imaging system has the potential to become
a noninvasive diagnostic tool for sputum and other specimens
from humans with suspected tuberculosis infections. The AFB
smear detects 5000–10 000 bacilli/mL in sputum compared
with REF, which can detect a minimum of 100 bacilli under
ideal laboratory conditions in just a few hours.
Volatile organic compounds (VOCs) in breath are also
being investigated as novel diagnostic biomarkers for active
pulmonary tuberculosis [54, 55]. Recently, investigators at
Menssana Research analyzed breath VOCs in 226 symptomatic
high-risk patients from the United States, the Philippines,
and the United Kingdom, using gas chromatography/mass
spectroscopy [56]. Breath VOCs contained apparent biomar-
kers of active pulmonary tuberculosis composed of oxidative
stress products (alkanes and alkane derivatives) and volatile
metabolites of M. tuberculosis (cyclohexane and benzene
derivatives), which identified active pulmonary tuberculosis
with 85% accuracy in the symptomatic high-risk subjects
evaluated in these field studies. Additional research is needed
to fully evaluate the specificity of VOCs for M. tuberculosis in
comparison with other disease-causing mycobacteria. None-
theless, preliminary data are encouraging for this ‘‘nose-based’’
technology for diagnosing active tuberculosis.
Aerosol-based novel diagnostics for tuberculosis are also
being explored. Investigators at Livermore Instruments are
evaluating a single-particle laser desorption/ionization time-
of-flight mass spectrometry tool for diagnosis. This bio-
aerosol mass spectrometry (BAMS) system was originally
designed for environmental and biodefense activities. Pilot
preclinical data were presented to suggest that M. tuberculosis
particles could be identified in bioaerosol generated by the
cough of an infectious tuberculosis patient [57, 58]. At this
time, BAMS systems are large and costly. However, with
additional engineering, this reagent-free, rapid (,2 minutes
per patient) platform could significantly transform current
approaches to screening for tuberculosis.
This workshop session discussed a number of paradigm-
changing approaches that need additional research. Of im-
portance were research and development efforts to move
accurate diagnostics into the primary care setting. Significant
additional research is needed before we can shift sites of
active tuberculosis diagnosis to communities, pharmacies,
and general health clinics. If this is not possible, could ul-
tradecentralization of diagnostics be at least matched to the
systems in place for directly observed therapy? Other ques-
tions were as follows: Could novel technologies, such as the
breath- and aerosol-based rapid diagnostics, provide the
opportunity to shift our approach to case detection and
screening, from passive to active, from individual to mass?
Can simple, affordable, POC diagnostics that are found to
have high sensitivity but marginal specificity still be useful as
referral tests for additional examination? If so, how might
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they be implemented? Last, the proportion of research and
development in tuberculosis diagnostics that should be di-
rected toward drug-susceptible vs drug-resistant tuberculo-
sis remains unresolved and is highly setting dependent.
Clearly, approaches that address these issues together are
desirable. In support of this, more and better mechanisms
are needed to coordinate the actions of studies and the
funding process. The funding mechanisms and agencies that
exist should make a greater effort to support and supplement
one another in order to implement projects as part of
a global architecture in healthcare.
MAXIMIZING AND OPTIMIZING RESEARCH
THROUGH COORDINATION AND
COLLABORATION
A number of existing resources can assist tuberculosis re-
searchers in their efforts to identify new or optimize existing
diagnostic technologies. Biospecimens are available to re-
searchers through the tuberculosis specimen bank of WHO’s
Special Programme for Research in Tropical Diseases (http://
apps.who.int/tdr/svc/diseases/tuberculosis/specimen-bank). The
National Disease Research Interchange (NDRI) is another
resource for biospecimens. NDRI, a nonprofit NIH-funded
organization, supports biomedical research through the re-
covery, preservation, and distribution of human biospeci-
mens. NDRI’s network of tissue acquisition centers provides
a range of normal and diseased biospecimens that are pro-
cured, preserved, and shipped according to investigator-
specified criteria. All biospecimens are accompanied by
extensive medical and social history data. More recently,
a tuberculosis-specific biobanking initiative, the Consortium
for TB Biomarkers (CTB2), was launched to facilitate bio-
marker discovery, in particular in the arena of markers of
treatment response. With initial funding from the FDA, CTB2
is being developed by 3 organizations central to tuberculosis
clinical drug development: NIAID’s AIDS Clinical Trials
Group, CDC’s Tuberculosis Trials Consortium, and the
Global Alliance for TB Drug Development. The CTB2 and its
affiliated networks have agreed on a core set of samples to be
collected, processed, and stored, including use of common data
elements obtained from well-characterized patients enrolled in
randomized, controlled tuberculosis treatment trials [44].
In order to optimally interpret the contribution of and
advancement provided by new tuberculosis diagnostics over
existing techniques, the clinical trials and field studies used to
evaluate them should be designed, implemented, and reported
according to universally accepted standards. Although most
tuberculosis diagnostic studies report sensitivity and specificity,
reporting is often not standardized and few have a random-
ized, controlled design. Use of culture as a gold standard for
reference is imperfect, and patient outcomes may be missing
from evaluations of tuberculosis diagnostics. Heterogeneity
of trial design and populations complicate cross-study compar-
isons or meta-analyses. Standards for the Reporting of Diag-
nostic accuracy studies (STARD) were designed to improve
the accuracy and completeness of diagnostic studies, permit
readers to evaluate the potential bias in the study, and assess
generalizability [59]. The STARD statement includes a checklist
of 25 items and recommends the use of a flow diagram to
follow study design and patients. Widespread adoption of
such standards, together with harmonized definitions, assess-
ment of clinical impact, and perhaps even standardized quality
assurance, would advance the field.
CONCLUSIONS AND RECOMMENDATIONS
Although there is significant work under way to develop
new diagnostic assays and devices for tuberculosis, a rapid,
accurate, POC, low-cost diagnostic has yet to be realized.
Because tuberculosis principally affects people in limited-
resource settings, for any new tuberculosis diagnostic to have
major public health impact, simplicity and low cost will be as
important as analytical accuracy. Tuberculosis diagnostics
should also be assessed in terms of clinical impact beyond
assessments of microbiological performance. Unfortunately,
the current tuberculosis diagnostic research literature largely
neglects the impact of diagnostic tests on patient-important
diagnoses and outcomes [60].
Through international input and consensus, the Stop TB
Partnership of WHO is developing a Global TB Research
Roadmap (http://www.stoptb.org/global/research/) that aims
to delineate priority research questions that need to be criti-
cally addressed for improved tuberculosis control, with the
goal of elimination by 2050. The Roadmap recognizes that
cross-disciplinary approaches spanning the continuum of
research across all disciplines from basic to implementation
science are required to achieve this goal. The Roadmap is 1 of
the main objectives of the TB Research Movement, a global
initiative of the Stop TB Partnership. The TB Research Move-
ment provides leadership and advocacy to mobilize increased
resources in support of a coherent and comprehensive global
tuberculosis research agenda, as well as a forum for researchers,
funders, and implementers of tuberculosis research to coor-
dinate plans and actions that will ensure research needs are
addressed, opportunities prioritized, and gaps filled. Within
the aegis of this initiative, proactive participation and orga-
nization of key groups involved in tuberculosis research are
needed to construct and implement strategies to harmonize
study design and data definitions and to effectively share
information about ongoing and planned studies worldwide.
At a minimum, this type of communication and coordination
for observational cohort studies and phase 2 and 3 clinical
trials are urgently needed. Given the substantial investment
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from many diverse groups, including US government agencies,
coordination of research and clinical evaluations in this field has
the potential to accelerate advances efficiently and economically.
Rapid development, assessment, and adoption of these di-
agnostic technologies require defining the critical path and
aligning key stakeholders and their respective roles so as to fa-
cilitate the progression from development to implementation.
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